MarginsXMarginsX
Home › Markets › Health Care › IRD

Opus Genetics Inc. (IRD)

IRD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.04
+1.51% on the day
Market cap
$390.5M
Small cap
Revenue · 2025
$14.2M
+29.1% on 2024
Net income · 2025
-$49.6M
-349.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1228627/000114036126009247/0001140361-26-009247-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIRD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001228627
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$14.2M
Net income-$49.6M
Operating income-$38.6M
Net margin-349.3%
Operating margin-271.9%
Revenue growth+29.1%
Cash$45.1M
Total assets$50.2M
P/E (computed)Net income was not positive
P/S (computed)27.5×

Warning signs

Cash runway
22.0 months
$89.0M cash at September 30, 2026
Share count, 1 year
+40.2%
2025-11-10 to 2026-11-06 · +327.0% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$16.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$89.0M cash; operating cash flow -$12.1M a quarter.Report 2026-09-30
Shares outstanding96,654,336 (2026-11-06); 68,964,208 a year earlier; 22,637,600 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-08-07
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Detroit, Michigan, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $324K, sold $16.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.1M-$46.5M-$14.0M$89.0M$35.7M$7.9M10-Q 2026-11-10
Q2 2026
2026-06-30
$755K-$8.1M-$11.9M$88.8M$35.3M$9.9M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.2M-$65.5M-$12.7M$60.0M$1.2M$12.0M10-Q 2026-05-12
Q4 2025
2025-12-31
$3.9M-$16.5M-$9.8M$45.1M$1.1M$14.2M10-K 2026-03-12
Q3 2025
2025-09-30
$3.1M-$17.5M-$6.2M$30.8M$1.1M$14.6M10-Q 2026-11-10
Q2 2025
2025-06-30
$2.9M-$7.4M-$10.3M$32.4M$1.0M$15.4M10-Q 2026-08-06
Q1 2025
2025-03-31
$4.4M-$8.2M-$9.0M$41.8MNo debt tags$13.7M10-Q 2026-05-12
Q4 2024
2024-12-31
$4.3M-$35.1M-$7.4M$30.3M$0$11.0M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-07
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-03-23

Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.8%
1 month-6.1%
3 months+7.0%
Year to date+98.0%
1 year+115.1%
From 52-week high-34.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PEPGPepGen Inc.$4.19-3.90%$395.0M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
PRTAProthena Corporation plc$7.97-2.33%$409.3M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier